Aclaris Therapeutics, Inc. has submitted an Investigational New Drug (IND) Application to the U.S. FDA for ATI-450, an oral MK2 inhibitor, for the treatment of rheumatoid arthritis (RA). If the IND is allowed by the FDA, Aclaris plans to initiate a Phase 1 clinical trial of ATI-450 in the second half of 2019. 

“We are very pleased to have this IND under review by the FDA,” said Dr. Neal Walker, President & Chief Executive Officer of Aclaris. “We look forward to beginning the development of ATI-450 as a potential treatment for rheumatoid arthritis and other potential indications driven by TNFα, IL-1β, IL-6, or IL-8. We believe there is an important need to provide additional treatment options for rheumatoid arthritis to improve overall patient care.”

ATI-450, an investigational medicine formerly known as CDD-450, would be the first novel compound created by Confluence Discovery Technologies, Inc., our indirect wholly owned subsidiary, to enter the clinical phase of development.